{"id":1798,"date":"2000-10-01T12:10:00","date_gmt":"2000-10-01T10:10:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/pure-red-cell-aplasia-nach-behandlung-eines-patienten-mit-follikulaerem-non-hodgkin-lymphom-mit-rituximab-und-polychemotherapie"},"modified":"2000-10-01T12:10:00","modified_gmt":"2000-10-01T10:10:00","slug":"pure-red-cell-aplasia-nach-behandlung-eines-patienten-mit-follikulaerem-non-hodgkin-lymphom-mit-rituximab-und-polychemotherapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/pure-red-cell-aplasia-nach-behandlung-eines-patienten-mit-follikulaerem-non-hodgkin-lymphom-mit-rituximab-und-polychemotherapie","title":{"rendered":"&#8222;Pure red cell aplasia&#8220; nach Behandlung eines Patienten mit follikul\u00e4rem Non-Hodgkin-Lymphom mit Rituximab und Polychemotherapie"},"content":{"rendered":"<p>\u00dcber eine bisher nicht beschriebene unerw\u00fcnschte Arzneimittelwirkung (UAW), die in engem zeitlichen Zusammenhang mit der Gabe des monoklonalen Antik\u00f6rpers Rituximab (MabThera) aufgetreten war, berichteten k\u00fcrzlich amerikanische Autoren (Sharma, V.R., et al.: Blood 2000, 96, 1184). Rituximab ist in Europa seit 1998 zur Behandlung chemotherapieresistenter oder rezidivierter follikul\u00e4rer Non-Hodgkin-Lymphome (NHL) zugelassen (vgl. AMB 2000, 34, 61b); [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcber eine bisher nicht beschriebene unerw\u00fcnschte Arzneimittelwirkung (UAW), die in engem zeitlichen Zusammenhang mit der Gabe des monoklonalen Antik\u00f6rpers Rituximab (MabThera) aufgetreten war, berichteten k\u00fcrzlich amerikanische Autoren (Sharma, V.R., et al.: Blood 2000, 96, 1184). Rituximab ist in Europa seit 1998 zur Behandlung chemotherapieresistenter oder rezidivierter follikul\u00e4rer Non-Hodgkin-Lymphome (NHL) zugelassen (vgl. AMB 2000, 34, 61b); [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1278,1358,1378,1394,3974,3973,798],"class_list":["post-1798","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aplastische-anaemie","tag-b-zell-lymphom","tag-b-zell-non-hodgkin-lymphom","tag-non-hodgkin-lymphom","tag-parvovirus-b19","tag-pure-red-cell-aplasia","tag-rituximab"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1798"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1798\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}